{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:26:21Z","timestamp":1778696781139,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10067-020-05079-3","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:37:41Z","timestamp":1589629061000},"page":"3287-3294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2012-2307","authenticated-orcid":false,"given":"Anna M.","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6839-5948","authenticated-orcid":false,"given":"Jamie N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,16]]},"reference":[{"issue":"11","key":"5079_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050046","volume":"7","author":"E Krishnan","year":"2012","unstructured":"Krishnan E (2012) Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One 7(11):e50046. https:\/\/doi.org\/10.1371\/journal.pone.0050046","journal-title":"PLoS One"},{"issue":"2","key":"5079_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s11926-012-0240-z","volume":"14","author":"MS Lipkowitz","year":"2012","unstructured":"Lipkowitz MS (2012) Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep 14(2):179\u2013188. https:\/\/doi.org\/10.1007\/s11926-012-0240-z","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"5079_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000089440","volume":"24","author":"T Nakagawa","year":"2006","unstructured":"Nakagawa T, Mazzali M, Kang DH, Sanchez-Lozada LG, Herrera-Acosta J, Johnson RJ (2006) Uric acid--a uremic toxin? Blood Purif 24(1):67\u201370. https:\/\/doi.org\/10.1159\/000089440","journal-title":"Blood Purif"},{"key":"5079_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2369-15-122","volume":"15","author":"L Li","year":"2014","unstructured":"Li L, Yang C, Zhao YL, Zeng XX, Liu F, Fu P (2014) Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:12. https:\/\/doi.org\/10.1186\/1471-2369-15-122","journal-title":"BMC Nephrol"},{"issue":"6","key":"5079_CR5","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1681\/ASN.2007101075","volume":"19","author":"DE Weiner","year":"2008","unstructured":"Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS (2008) Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19(6):1204\u20131211. https:\/\/doi.org\/10.1681\/ASN.2007101075","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"5079_CR6","doi-asserted-by":"publisher","first-page":"e0170393","DOI":"10.1371\/journal.pone.0170393","volume":"12","author":"C-W Tsai","year":"2017","unstructured":"Tsai C-W, Lin S-Y, Kuo C-C, Huang C-C (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One 12(1):e0170393\u2013e0170393. https:\/\/doi.org\/10.1371\/journal.pone.0170393","journal-title":"PLoS One"},{"issue":"4","key":"5079_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","volume":"169","author":"CY Hsu","year":"2009","unstructured":"Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS (2009) Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 169(4):342\u2013350. https:\/\/doi.org\/10.1001\/archinternmed.2008.605","journal-title":"Arch Intern Med"},{"issue":"9","key":"5079_CR8","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.metabol.2016.05.009","volume":"65","author":"X Xia","year":"2016","unstructured":"Xia X, Luo Q, Li B, Lin Z, Yu X, Huang F (2016) Serum uric acid and mortality in chronic kidney disease: a systematic review and meta-analysis. Metabolism 65(9):1326\u20131341. https:\/\/doi.org\/10.1016\/j.metabol.2016.05.009","journal-title":"Metabolism"},{"issue":"10","key":"5079_CR9","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64(10):1431\u20131446. https:\/\/doi.org\/10.1002\/acr.21772","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"5079_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5079_CR11","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s10067-018-4243-7","volume":"37","author":"JA Singh","year":"2018","unstructured":"Singh JA (2018) Goals of gout treatment: a patient perspective. Clin Rheumatol 37(9):2557\u20132566. https:\/\/doi.org\/10.1007\/s10067-018-4243-7","journal-title":"Clin Rheumatol"},{"issue":"2","key":"5079_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","volume":"124","author":"RT Keenan","year":"2011","unstructured":"Keenan RT, O'Brien WR, Lee KH, Crittenden DB, Fisher MC, Goldfarb DS, Krasnokutsky S, Oh C, Pillinger MH (2011) Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 124(2):155\u2013163. https:\/\/doi.org\/10.1016\/j.amjmed.2010.09.012","journal-title":"Am J Med"},{"issue":"1","key":"5079_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47(1):51\u201359. https:\/\/doi.org\/10.1053\/j.ajkd.2005.10.006","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"5079_CR14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/cjn.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388\u20131393. https:\/\/doi.org\/10.2215\/cjn.01580210","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"5079_CR15","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1681\/ASN.2010111185","volume":"22","author":"MP Kao","year":"2011","unstructured":"Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD (2011) Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 22(7):1382\u20131389. https:\/\/doi.org\/10.1681\/ASN.2010111185","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5079_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000331453","volume":"35","author":"Y Shi","year":"2012","unstructured":"Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, Yang Q, Johnson RJ, Yu X (2012) Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 35(3):153\u2013160. https:\/\/doi.org\/10.1159\/000331453","journal-title":"Kidney Blood Press Res"},{"issue":"4","key":"5079_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/hdi.12313","volume":"19","author":"Y Tsuruta","year":"2015","unstructured":"Tsuruta Y, Kikuchi K, Tsuruta Y, Sasaki Y, Moriyama T, Itabashi M, Takei T, Uchida K, Akiba T, Tsuchiya K, Nitta K (2015) Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: a randomized controlled study. Hemodial Int 19(4):514\u2013520. https:\/\/doi.org\/10.1111\/hdi.12313","journal-title":"Hemodial Int"},{"issue":"6","key":"5079_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66(6):945\u2013950. https:\/\/doi.org\/10.1053\/j.ajkd.2015.05.017","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"5079_CR19","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s10157-015-1095-1","volume":"19","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Nakayama M, Kanno M, Kimura H, Watanabe K, Tani Y, Hayashi Y, Asahi K, Terawaki H, Watanabe T (2015) Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol 19(6):1044\u20131053. https:\/\/doi.org\/10.1007\/s10157-015-1095-1","journal-title":"Clin Exp Nephrol"},{"issue":"9","key":"5079_CR20","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s11255-019-02243-w","volume":"51","author":"M Alshahawey","year":"2019","unstructured":"Alshahawey M, Shaheen SM, Elsaid T, Sabri NA (2019) Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study. Int Urol Nephrol 51(9):1649\u20131657. https:\/\/doi.org\/10.1007\/s11255-019-02243-w","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"5079_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76(1):47\u201356. https:\/\/doi.org\/10.1016\/0002-9343(84)90743-5","journal-title":"Am J Med"},{"issue":"5","key":"5079_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","volume":"20","author":"N Dalbeth","year":"2007","unstructured":"Dalbeth N, Stamp L (2007) Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 20(5):391\u2013395. https:\/\/doi.org\/10.1111\/j.1525-139X.2007.00270.x","journal-title":"Semin Dial"},{"issue":"11","key":"5079_CR23","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/j.clinthera.2009.11.033","volume":"31","author":"ME Ernst","year":"2009","unstructured":"Ernst ME, Fravel MA (2009) Febuxostat: a selective xanthine-oxidase\/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin Ther 31(11):2503\u20132518. https:\/\/doi.org\/10.1016\/j.clinthera.2009.11.033","journal-title":"Clin Ther"},{"issue":"4 Suppl 2","key":"5079_CR24","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/RHU.0b013e31821d36f2","volume":"17","author":"T Hosoya","year":"2011","unstructured":"Hosoya T, Ohno I (2011) A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study. J Clin Rheumatol 17(4 Suppl 2):S27\u2013S34. https:\/\/doi.org\/10.1097\/RHU.0b013e31821d36f2","journal-title":"J Clin Rheumatol"},{"issue":"10","key":"5079_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/hr.2014.107","volume":"37","author":"Y Shibagaki","year":"2014","unstructured":"Shibagaki Y, Ohno I, Hosoya T, Kimura K (2014) Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertens Res 37(10):919\u2013925. https:\/\/doi.org\/10.1038\/hr.2014.107","journal-title":"Hypertens Res"},{"issue":"3","key":"5079_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.23876\/j.krcp.2017.36.3.274","volume":"36","author":"S Kim","year":"2017","unstructured":"Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, Cho CR, Han SY (2017) Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: a systematic review and meta-analysis. Kidney Res Clin Pract 36(3):274\u2013281. https:\/\/doi.org\/10.23876\/j.krcp.2017.36.3.274","journal-title":"Kidney Res Clin Pract"},{"issue":"3","key":"5079_CR27","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3892\/etm.2018.6367","volume":"16","author":"X Liu","year":"2018","unstructured":"Liu X, Liu K, Sun Q, Wang Y, Meng J, Xu Z, Shi Z (2018) Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: a systematic review and meta-analysis. Exp Ther Med 16(3):1859\u20131865. https:\/\/doi.org\/10.3892\/etm.2018.6367","journal-title":"Exp Ther Med"},{"issue":"7","key":"5079_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"5079_CR29","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"11","key":"5079_CR30","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1007\/s10067-014-2745-5","volume":"33","author":"Y Tsuruta","year":"2014","unstructured":"Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K (2014) Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin Rheumatol 33(11):1643\u20131648. https:\/\/doi.org\/10.1007\/s10067-014-2745-5","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5079_CR31","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1007\/s10157-018-1580-4","volume":"22","author":"T Tsuji","year":"2018","unstructured":"Tsuji T, Ohishi K, Takeda A, Goto D, Sato T, Ohashi N, Fujigaki Y, Kato A, Yasuda H (2018) The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol 22(6):1300\u20131308. https:\/\/doi.org\/10.1007\/s10157-018-1580-4","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"5079_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-018-2051-2","volume":"51","author":"J-W Lee","year":"2019","unstructured":"Lee J-W, Lee K-H (2019) Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol 51(3):467\u2013473. https:\/\/doi.org\/10.1007\/s11255-018-2051-2","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"5079_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jjcc.2014.12.017","volume":"66","author":"A Sezai","year":"2015","unstructured":"Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, Hata H, Shiono M (2015) Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). J Cardiol 66(4):298\u2013303. https:\/\/doi.org\/10.1016\/j.jjcc.2014.12.017","journal-title":"J Cardiol"},{"key":"5079_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2369-12-36","volume":"12","author":"MJ Fuldeore","year":"2011","unstructured":"Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E (2011) Chronic kidney disease in gout in a managed care setting. BMC Nephrol 12:36. https:\/\/doi.org\/10.1186\/1471-2369-12-36","journal-title":"BMC Nephrol"},{"issue":"2","key":"5079_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.30119","volume":"63","author":"LK Stamp","year":"2011","unstructured":"Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63(2):412\u2013421. https:\/\/doi.org\/10.1002\/art.30119","journal-title":"Arthritis Rheum"},{"issue":"13","key":"5079_CR36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L, Investigators C (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378(13):1200\u20131210. https:\/\/doi.org\/10.1056\/NEJMoa1710895","journal-title":"N Engl J Med"},{"issue":"12","key":"5079_CR37","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s10067-017-3851-y","volume":"36","author":"BJ Paul","year":"2017","unstructured":"Paul BJ, Anoopkumar K, Krishnan V (2017) Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol 36(12):2637\u20132644. https:\/\/doi.org\/10.1007\/s10067-017-3851-y","journal-title":"Clin Rheumatol"},{"issue":"2","key":"5079_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/BOR.0000000000000367","volume":"29","author":"LK Stamp","year":"2017","unstructured":"Stamp LK (2017) Major unanswered questions in the clinical gout field. Curr Opin Rheumatol 29(2):171\u2013177. https:\/\/doi.org\/10.1097\/BOR.0000000000000367","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"5079_CR39","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1007\/s10067-019-04737-5","volume":"38","author":"Z Mu","year":"2019","unstructured":"Mu Z, Wang W, Wang J, Lv W, Chen Y, Wang F, Yu X, Wang Y, Cheng B, Wang Z (2019) Predictors of poor response to urate-lowering therapy in patients with gout and hyperuricemia: a post-hoc analysis of a multicenter randomized trial. Clin Rheumatol 38(12):3511\u20133519. https:\/\/doi.org\/10.1007\/s10067-019-04737-5","journal-title":"Clin Rheumatol"},{"key":"5079_CR40","doi-asserted-by":"publisher","unstructured":"Lin YJ, Lin SY, Lin CH, Wang ST, Chang SS (2020) Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. Clin Rheumatol:1\u201316. https:\/\/doi.org\/10.1007\/s10067-019-04893-8","DOI":"10.1007\/s10067-019-04893-8"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05079-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05079-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05079-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T13:15:39Z","timestamp":1633094139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05079-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,16]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5079"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05079-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,16]]},"assertion":[{"value":"3 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}